Eupraxia Pharmaceuticals announced positive 12-week and 36-week tissue health data from the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Patients who received the highest dose showed near-complete improvement in tissue health. Over 60% of patients achieved clinical remission by 8 weeks and maintained it through 52 weeks. EP-104GI was well tolerated with no Serious Adverse Events reported. The Phase 2b part of the RESOLVE trial is currently recruiting, with top-line data expected in Q3 2026. EoE affects more than 450,000 people in the US and has been identified as rapidly increasing in both incidence and prevalence. Eupraxia Pharmaceuticals reports positive results from trial of EP-104GI for esophageal disease. Patients saw near complete improvement in tissue health with highest dose. Majority achieved clinical remission by 8 weeks and maintained through 52 weeks. Drug well tolerated with no SAEs or oral candidiasis. Trial met primary endpoint and three of four secondary endpoints. Company developing pipeline of long-acting formulations for other inflammatory joint indications and oncology. For more information, visit www.eupraxiapharma.com. Forward-looking statements included in news release. Contact James Meikle at 236-330-7084 or [email protected] for inquiries. Contact Kevin Gardner at 617-283-2856 or [email protected] on behalf of Eupraxia Pharmaceuticals Inc. At week 12 of the trial, patients receiving the highest dose of EP-104GI showed significant improvement in tissue health. Lower doses also maintained positive results up to week 36. Clinical remission was achieved in 8 weeks and maintained for 52 weeks in most patients. The drug was well tolerated, with over 200 patient-months of follow-up showing no Serious Adverse Events or cases of oral candidiasis.

Read more at Globe Newswire

EP-104GI Shows Positive Results in Tissue Health Improvement Trial
Patients in trial show significant improvement in tissue health at week 12, with best results seen in highest dosed group. Lower doses also maintain improvements up to week 36. Clinical remission achieved by 8 weeks and sustained through 52 weeks in majority of patients. Over 200 patient-months of follow-up show no Serious Adverse Events or cases of oral candidiasis. : Eupraxia Pharmaceuticals Reports Positive Tissue Health